Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review H1 2015


#307253

515pages

Global Markets Direct

$ 2000

In Stock

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review H1 2015

Summary

Global Markets Directs Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review H1 2015 provides an overview of the Head And Neck Cancer Squamous Cell Carcinomas therapeutic pipeline

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action (MoA) route of administration (RoA) and molecule type along with latest updates and featured news and press releases It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3000 indications The report is built using data and information sourced from Global Markets Directs proprietary databases Company/University websites SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources put together by Global Markets Directs team Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information Additionally processes including live news & deals tracking browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease

Scope

- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
- The report reviews key pipeline products under drug profile section which includes product description MoA and R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target MoA route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information analysis and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 10
Global Markets Direct Report Coverage 10
Head And Neck Cancer Squamous Cell Carcinoma Overview 11
Therapeutics Development 12
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview 12
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 13
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 14
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 20
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 25
Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 32
Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 33
AbbVie Inc 33
Acceleron Pharma Inc 34
Advaxis Inc 35
Altor BioScience Corporation 36
Amgen Inc 37
Ascenta Therapeutics Inc 38
Astex Pharmaceuticals Inc 39
AstraZeneca Plc 40
AVEO Pharmaceuticals Inc 41
BIND Therapeutics Inc 42
Boehringer Ingelheim GmbH 43
Bristol-Myers Squibb Company 44
CEL-SCI Corporation 45
Celldex Therapeutics Inc 46
Celltrion Inc 47
Centrose Llc 48
Critical Outcome Technologies Inc 49
Daiichi Sankyo Company Limited 50
Eisai Co Ltd 51
Eli Lilly and Company 52
F Hoffmann-La Roche Ltd 53
Genentech Inc 54
Genexine Inc 55
GlaxoSmithKline Plc 56
Gliknik Inc 57
Glycotope GmbH 58
ImmunoGen Inc 59
Immunomedics Inc 60
Immunovative Therapies Ltd 61
Incyte Corporation 62
Innate Pharma SA 63
Inovio Pharmaceuticals Inc 64
Karyopharm Therapeutics Inc 65
Laboratoires Pierre Fabre SA 66
Mabion SA 67
MacroGenics Inc 68
MedImmune LLC 69
Merck & Co Inc 70
Merck KGaA 71
Mirati Therapeutics Inc 72
Molplex Ltd 73
Novartis AG 74
Oncolytics Biotech Inc 75
Onconova Therapeutics Inc 76
OncoSec Medical Inc 77
Oncovir Inc 78
Ono Pharmaceutical Co Ltd 79
OXiGENE Inc 80
Panacea Biotec Limited 81
PCI Biotech AS 82
Pfizer Inc 83
Shionogi & Co Ltd 84
Symphogen A/S 85
Synta Pharmaceuticals Corp 86
Takara Bio Inc 87
Threshold Pharmaceuticals Inc 88
VasGene Therapeutics Inc 89
VentiRx Pharmaceuticals Inc 90
Virttu Biologics Limited 91
Viventia Biotechnologies Inc 92
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 93
Assessment by Monotherapy Products 93
Assessment by Combination Products 94
Assessment by Target 95
Assessment by Mechanism of Action 100
Assessment by Route of Administration 104
Assessment by Molecule Type 106
Drug Profiles 108
ABBV-221 - Drug Profile 108
ABT-806 - Drug Profile 109
AdIL-24 - Drug Profile 110
ADXS-HPV - Drug Profile 111
afatinib - Drug Profile 115
AlloVax - Drug Profile 119
alpelisib - Drug Profile 121
ALT-803 - Drug Profile 123
AMG-228 - Drug Profile 125
AMG-319 - Drug Profile 126
Antibodies to Inhibit FRMD4A for Oncology - Drug Profile 128
Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 129
AT-406 - Drug Profile 130
AV-203 - Drug Profile 133
avelumab - Drug Profile 134
bleomycin sulfate - Drug Profile 136
BMS-986016 - Drug Profile 138
buparlisib hydrochloride - Drug Profile 139
capmatinib - Drug Profile 143
Cell Therapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 145
cetuximab - Drug Profile 146
cetuximab biobetter - Drug Profile 153
cetuximab biosimilar - Drug Profile 154
cetuximab biosimilar - Drug Profile 155
cetuximab biosimilar - Drug Profile 156
cetuximab biosimilar - Drug Profile 157
COTI-2 - Drug Profile 158
dalantercept - Drug Profile 161
Dendritic Cell Therapy for Oncology - Drug Profile 163
DNA IL-12 - Drug Profile 165
docetaxel - Drug Profile 168
DPV-001 - Drug Profile 170
DTP-348 - Drug Profile 172
duligotuzumab - Drug Profile 174
durvalumab - Drug Profile 176
durvalumab + tremelimumab - Drug Profile 179
EDC-2 - Drug Profile 181
enoblituzumab - Drug Profile 182
epacadostat - Drug Profile 184
everolimus - Drug Profile 186
ficlatuzumab - Drug Profile 192
futuximab - Drug Profile 195
ganetespib - Drug Profile 197
Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile 201
Gene Therapy to Activate p53 for Oncology - Drug Profile 202
GL-0817 - Drug Profile 203
golvatinib tartrate - Drug Profile 204
GS-10 - Drug Profile 206
GSK-2636771 - Drug Profile 208
GSK-2849330 - Drug Profile 209
GX-051 - Drug Profile 210
HF-10 - Drug Profile 211
HSV-1716 - Drug Profile 213
IC-1001 - Drug Profile 216
IMGN-289 - Drug Profile 217
INO-3106 - Drug Profile 218
INO-3112 - Drug Profile 219
IPH-2201 - Drug Profile 220
JX-929 - Drug Profile 222
KGP-94 - Drug Profile 223
Leukocyte Interleukin - Drug Profile 224
LGK-974 - Drug Profile 227
LJM-716 - Drug Profile 228
lumretuzumab - Drug Profile 230
LY-2606368 - Drug Profile 232
MEDI-6469 - Drug Profile 233
merestinib - Drug Profile 235
MGCD-265 - Drug Profile 236
Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 238
Monoclonal Antibody for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 240
Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 241
motolimod - Drug Profile 242
MV-NIS - Drug Profile 244
nilotinib - Drug Profile 246
nimorazole - Drug Profile 249
nimotuzumab - Drug Profile 251
nivolumab - Drug Profile 254
olaparib - Drug Profile 260
onalespib - Drug Profile 264
Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 267
oportuzumab monatox - Drug Profile 269
panitumumab - Drug Profile 271
patritumab - Drug Profile 274
pelareorep - Drug Profile 276
pembrolizumab - Drug Profile 281
pemetrexed disodium - Drug Profile 288
pexastimogene devacirepvec - Drug Profile 294
PF-04518600 - Drug Profile 296
Poly-ICLC - Drug Profile 297
Recombinant Peptide to Target EGFR for Oncology - Drug Profile 300
Recombinant Protein for Oncology - Drug Profile 301
rigosertib sodium - Drug Profile 302
S-488210 - Drug Profile 307
sacituzumab govitecan - Drug Profile 308
selinexor - Drug Profile 309
Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 314
Small Molecules to Inhibit 30S RNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer - Drug Profile 315
Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 316
TH-4000 - Drug Profile 317
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 319
urelumab - Drug Profile 321
vandetanib - Drug Profile 323
varlilumab - Drug Profile 329
Vas-01 - Drug Profile 331
vinflunine ditartrate - Drug Profile 333
Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 335
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 493
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 497
Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 499
Featured News & Press Releases 499
Appendix 507
Methodology 507
Coverage 507
Secondary Research 507
Primary Research 507
Expert Panel Validation 507
Contact Us 507
Disclaimer 508

List of Tables
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma H1 2015 19
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis H1 2015 20
Number of Products under Development by Companies H1 2015 22
Number of Products under Development by Companies H1 2015 (Contd1) 23
Number of Products under Development by Companies H1 2015 (Contd2) 24
Number of Products under Development by Companies H1 2015 (Contd3) 25
Number of Products under Development by Companies H1 2015 (Contd4) 26
Number of Products under Investigation by Universities/Institutes H1 2015 28
Comparative Analysis by Late Stage Development H1 2015 29
Comparative Analysis by Clinical Stage Development H1 2015 30
Comparative Analysis by Early Stage Development H1 2015 31
Products under Development by Companies H1 2015 32
Products under Development by Companies H1 2015 (Contd1) 33
Products under Development by Companies H1 2015 (Contd2) 34
Products under Development by Companies H1 2015 (Contd3) 35
Products under Development by Companies H1 2015 (Contd4) 36
Products under Development by Companies H1 2015 (Contd5) 37
Products under Development by Companies H1 2015 (Contd6) 38
Products under Investigation by Universities/Institutes H1 2015 39
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc H1 2015 40
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma Inc H1 2015 41
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis Inc H1 2015 42
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Altor BioScience Corporation H1 2015 43
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc H1 2015 44
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ascenta Therapeutics Inc H1 2015 45
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Astex Pharmaceuticals Inc H1 2015 46
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc H1 2015 47
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals Inc H1 2015 48
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by BIND Therapeutics Inc H1 2015 49
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH H1 2015 50
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company H1 2015 51
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation H1 2015 52
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celldex Therapeutics Inc H1 2015 53
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion Inc H1 2015 54
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose Llc H1 2015 55
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc H1 2015 56
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company Limited H1 2015 57
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co Ltd H1 2015 58
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company H1 2015 59
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F Hoffmann-La Roche Ltd H1 2015 60
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genentech Inc H1 2015 61
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine Inc H1 2015 62
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline Plc H1 2015 63
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik Inc H1 2015 64
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH H1 2015 65
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by ImmunoGen Inc H1 2015 66
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics Inc H1 2015 67
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies Ltd H1 2015 68
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation H1 2015 69
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma SA H1 2015 70
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals Inc H1 2015 71
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Karyopharm Therapeutics Inc H1 2015 72
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA H1 2015 73
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA H1 2015 74
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics Inc H1 2015 75
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune LLC H1 2015 76
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co Inc H1 2015 77
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA H1 2015 78
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc H1 2015 79
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd H1 2015 80
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG H1 2015 81
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc H1 2015 82
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics Inc H1 2015 83
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Inc H1 2015 84
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncovir Inc H1 2015 85
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd H1 2015 86
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OXiGENE Inc H1 2015 87
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited H1 2015 88
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS H1 2015 89
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc H1 2015 90
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co Ltd H1 2015 91
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S H1 2015 92
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Synta Pharmaceuticals Corp H1 2015 93
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc H1 2015 94
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals Inc H1 2015 95
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics Inc H1 2015 96
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals Inc H1 2015 97
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited H1 2015 98
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Biotechnologies Inc H1 2015 99
Assessment by Monotherapy Products H1 2015 100
Assessment by Combination Products H1 2015 101
Number of Products by Stage and Target H1 2015 103
Number of Products by Stage and Mechanism of Action H1 2015 108
Number of Products by Stage and Route of Administration H1 2015 112
Number of Products by Stage and Molecule Type H1 2015 114
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates H1 2015 342
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects H1 2015 500
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd1) H1 2015 501
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd2) H1 2015 502
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd3) H1 2015 503
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products H1 2015 504
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd1) H1 2015 505

List of Figures
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma H1 2015 19
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis H1 2015 20
Number of Products under Development by Companies H1 2015 21
Number of Products under Investigation by Universities/Institutes H1 2015 27
Comparative Analysis by Late Stage Development H1 2015 29
Comparative Analysis by Clinical Stage Development H1 2015 30
Comparative Analysis by Early Stage Products H1 2015 31
Assessment by Monotherapy Products H1 2015 100
Assessment by Combination Products H1 2015 101
Number of Products by Top 10 Targets H1 2015 102
Number of Products by Stage and Top 10 Targets H1 2015 102
Number of Products by Top 10 Mechanism of Actions H1 2015 107
Number of Products by Stage and Top 10 Mechanism of Actions H1 2015 107
Number of Products by Top 10 Routes of Administration H1 2015 111
Number of Products by Stage and Top 10 Routes of Administration H1 2015 111
Number of Products by Top 10 Molecule Types H1 2015 113
Number of Products by Stage and Top 10 Molecule Types H1 2015 113

NA

NA